<International Circulation>: What are your expectations for the upcoming release of ATP-IV guidelines on lipid-lowering therapy?

　　Prof. Rosenson: The National Heart， Lung， and Blood Institute have decided that they are only going to support scientific statements and that the formulation of guidelines will be directed at the professional societies. So though the ATP–IV committee had completed their report， this document is now going to be sent to the American College of Cardiology and the American Heart Association for further discussion. The ATP-IV committee had specific directives， which were to use clinical trial evidence and any information that was not part of a randomized double blind controlled trial with validated endpoints won’t be considered in their recommendations.So we should expect that the ATP-IV guidelines will be very scientifically based， and may miss the opportunity to provide clinical practice guidelines as was done in ATP I， II and III.

　　《国际循环》：您对即将发布的ATP-Ⅳ指南在降脂治疗方面有怎样的期待？

　　Rosenson教授：国家心脏、肺和血液研究所已经决定，他们将只作科学声明。指南的制订将由专业学会来进行。因此，尽管ATP-IV委员会已完成报告，其文件还是被送至ACC及AHA进行进一步的讨论。ATP-IV委员会在撰写报告时得到了明确指示，即推荐时要应用临床试验证据，而不能考虑非随机双盲对照试验的任何终点信息。因此，我们预计ATP-IV指南将主要为大家提供科学依据，可能无法像ATPⅠ、Ⅱ及Ⅲ那样转化为临床实践指南。